Browse > Article

Comparison of Some 3-(Substituted-Benzylidene)-1, 3-Dihydro-Indolin Derivatives as Ligands of Tyrosine Kinase Based on Binding Mode Studies and Biological Assay  

Olgen, Sureyya (Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ankara)
Publication Information
Archives of Pharmacal Research / v.29, no.11, 2006 , pp. 1006-1017 More about this Journal
Abstract
A series of 3-(substituted-benylidene)-1, 3-dihydro- indolin-2-one, 3-(substituted-benylidene)-1, 3-dihydro- indolin-2-thione and 2, 2'-dithiobis 3-(substituted-benylidene)-1, 3-dihydro-indole derivatives was investigated as inhibitor of $p60^{c-Src}$tyrosine kinase by performing receptor docking studies and inhibitory activity toward tyrosine phosphorylation. Some compounds were shown to be docked at the site, where the selective inhibitor PP1 [1-tert-Butyl-3-p-tolyl-1H-pyrazolo[3,4-d]pyrimidine-4-yl-amine] was embedded at the enzyme active site. Evaluation of all compounds for the interactions with the parameters of lowest binding energy levels, capability of hydrogen bond formations and superimposibility on enzyme active site by docking studies, it can be assumed that 3-(substituted-benzylidene)-1, 3-dihydro-indolin-2-one and thione derivatives have better interaction with enzyme active site then 2, 2'-dithiobis 3-(substituted-benzylidene)-1, 3-dihydro indole derivatives. The test results for the inhibitory activity against tyrosine kinase by Elisa method revealed that 3-(substituted-benylidene)-1, 3-dihydro- indolin-2-thione derivatives have more activity then 3-(substituted-benylidene)-1, 3-dihydro- indolin-2-one derivatives.
Keywords
Protein tyrosine kinase; $p60^{c-Src}$; N-Substituted indole derivatives; Dock 4.0;
Citations & Related Records

Times Cited By Web Of Science : 1  (Related Records In Web of Science)
Times Cited By SCOPUS : 1
연도 인용수 순위
1 Braud, E. M., Nourrisson, M. R., Tonnerre, A., Picot, C., LeBaut, G., Renard, P., Pfeiffer, B., and Tucker, G., Potential Inhibitors of angiogenesis. Part I: 3-(imidazolyl-4 (5)-ylmethylene) indolin-2-ones. J. Enzyme Inhib. Med. Chem., 18, 243-252 (2003)   DOI   ScienceOn
2 Coda, A. C., Invernizzi, A. G., Righetti, P. P., and Tacconi, G., (Z)- and (E)-Arylindene-1,3-dihydro indol-2-ones: configuration, conformation, and infrared carbonyl stretching frequencies. J. Chem. Soc. Perkin Trans, 2, 615-619 (1984)
3 Cortes-Funes, H., Antiangiogenic agents. Drugs of Today, 38, 11-19 (2002)
4 Ewing T. J. A., Makino, S., Skillman, A. G., and Kuntz, I. D., Dock 4.0: Search strategies for automated molecular docking flexible molecule databases. J. Comp.-Aid. Mol. Des., 15, 411-428 (2001)   DOI   ScienceOn
5 Fabbro, D., Parkinson, D., and Matter, A., Protein tyrosine kinase inhibitors: new treatment modalities. Curr. Opin. Pharmacol. 2, 374-381 (2002)   DOI   ScienceOn
6 Fong, T. A. T., Shawver, L. K., App, H., Sun, L., Tang, C., Rice, A., Kim, Y. H., Schreck, R., Chen, J., Dowd, B., Suto, E., Vasile, S., Wang, X., Hirth, K. P., and McMahon, G., SU 5416: a potent and selective Flk-1/KDR kinase inhibitor that blocks Flk-1 phosphorylation, endotelhial cell mitogenesis, and tumor growth. Proc. Am. Assoc. Cancer Res., 39, 560-567 (1998)
7 Fong, T. A. T., Shawer, L. K., Sun, L., Tang, C., App, H., Powell, T. J., Kim, Y. H., Schreck, R., Wang, X., Risau, W., Ullrich, A., Hirth, K. P., and McMahon, G., SU 5416: is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth for multiple tumor types. J. Cancer Res., 59, 99-106 (1999)
8 Roussidis, A. E. and Karamanos, N. K., Inhibition of receptor tyrosine kinase-based signal transduction as specific target for cancer treatment. In vivo, 16, 459-470 (2002)
9 Taylor, V. C., Buckley, C. D., Douglas, M., Cody, A. J., Simmons, D. L., and Freeman, S. D., The myeloid-specific sialic acid binding receptor, CD33, associated with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J. Biol. Chem., 274, 11505-11512 (1999)   DOI   ScienceOn
10 Olgen, S., Akaho, E., and Nebioglu, D., Synthesis and antityrosine activity of 3-(substituted-benzylidene)-1, 3-dihydroindolin derivatives: investigation of their role against $p60^{c-Src}$ receptor tyrosine kinase with the application of receptor docking studies. Farmaco, 60, 497-506 (2005)   DOI   ScienceOn
11 Traxler, P. and Lyndon, N., Recent advances in protein tyrosine kinase inhibitors. Drugs of the Future, 20, 1261-1274 (1995)   DOI
12 Rewcastle, G. W., Palmer, B. D., Dobrusin, E. M., Fry, D. W., Kraker, A. J., and Denny, W. A., Tyrosine kinase inhibitors. 3. Structure-activity relationships for inhibition of protein tyrosine kinases by nuclear-substituted derivatives of 2, 2'-dithiobis (1-methyl-N-phenyl-1H-indole-3-carboxamide). J. Med. Chem., 37, 2033-2042 (1994)   DOI   ScienceOn
13 Folkman, J., Tumor angiogenesis. Adv. Cancer Res., 43, 175- 203 (1985)   DOI
14 Terrence, R. B., Protein-tyrosine kinase inhibitors. Drugs of the Future, 17, 119-131 (1992)
15 Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., and Connelly, P. A., Discovery of a novel, potent and src family selective tyrosine kinase inhibitor. J. Biol. Chem., 271, 695-701 (1996)   DOI
16 Ewing T. J. A. and Kuntz, I. D., Critical evaluation of search algorithms for automated molecular docking and database screening. J. Comput. Chem., 18, 1175-1189 (1997)   DOI   ScienceOn
17 Lyne, P. D., Structure-based virtual screening: an overview. Drug Discovery Today, 7, 1047-1055 (2002)   DOI   ScienceOn
18 Noonberg, S. B. and Benz, C. C., Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily. Drugs, 59, 753-767 (2000)   DOI   ScienceOn
19 Thompson, A. M., Rewcastle, G. W., Boushelle, S. L., Hartl, B. G., Kraker, A. J., Lu, G. H., Batley, B. L., Panek, R. L., Showalter, H. D. H., and Denny, W. A., Synthesis and structure-activity relationships of 7-substituted 3-(2, 6-dichlorophenyl)-1, 6- naphthydrin-2 (1H)-ones as selective inhibitors of $p60^{c-Src}$. J. Med. Chem., 43, 3134-3147 (2000)   DOI   ScienceOn
20 Sun, Y, Ewing T. J. A., Skillman, A. G., and Kuntz, I. D., CombiDOCK: Structure-based combinatorial docking and library design. J. Comp.-Aid. Mol. Des., 12, 597-604 (1998)   DOI   ScienceOn
21 Khols, D. W. D., Fry, D. W., and Kraker, A. J., Inhibitors of tyrosine kinase. Curr. Opin. Oncol., 9, 562-568 (1997)   DOI
22 Zhu, X., Kim, J. L., Newcomb, J. R., Rose, P. E., Stover, D. R., Toledo, L. M., Zhao, H., and Morgenstern, K. A., Structural Analysis of the Lymphocyte-Specific Kinase Lck in Complex with Non-Selective and Src Family Selective Kinase. Structure, 7, 651-661 (1999)   DOI   ScienceOn
23 Hamby, J. M. and Showalter, H. D. H., Small molecule inhibitors of tumor promoted angiogenesis, including protein kinase inhibitors. Pharmacol. Ther., 82, 169-193 (1999)   DOI   ScienceOn
24 Sun, L., Tran, N., Liang, C., Tang, F., Rice, A., Schreck, R., Waltz, K., Shaever, L. K., McMahon, G., and Tang, C., Design, synthesis and evaluations of substituted 3-[(3- or 4- carboxy ethyl pyrrol-2-yl)methylindenyl]indolin-2-ones as inhibitors of VEGF, FGF and PDGF receptor tyrosine kinases. J. Med. Chem., 42, 5120-5130 (1999)   DOI   ScienceOn
25 Sun, L., Tran, N., Liang, C., Hubbard, S., Tang, F., Lipson, K., Schreck, R., Zhou, Y., McMahon, G., and Tang, C., Identification of substituted 3-[(4, 5, 6, 7-Tetrahydro-1H-indole-2-yl) methylene]-1, 3-hydroindole-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rb tyrosine kinases. J. Med. Chem., 43, 2655-2663 (2000)   DOI   ScienceOn
26 Taylor, R. D., Jewsbury, P. J., and Essex, J. W., A review of protein-small molecule docking methods. J. Comp.-Aid. Mol. Des., 16, 151-166 (2002)   DOI   ScienceOn
27 Akaho, E., Fujikawa, C., Runion, H. I., Hill, C. R., and Nakaho, H., A study on docking mode of hiv protease and their inhibitors. J. Chem. Software, 5, 147 -162 (1999)   DOI
28 Meng, E. C., Scoichet, B. K., and Kuntz, I. D., Automated docking with grid-base evaluation. J. Comput. Chem., 13, 505-524 (1992)   DOI
29 Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B. K., Hubbard, S. R., and Schlessinger, J., Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science, 276, 955-960 (1997)   DOI   ScienceOn
30 Sun, L., Tran, N., Tang, F., App, H., Hirth, P., McMahon, G., and Tang, C., Synthesis and biological evaluations of 3- substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular tyrosine kinases. J. Med. Chem., 41, 2588-2603 (1998)   DOI   ScienceOn
31 Levitzki, A. and Grazit, A., Tyrosine kinase inhibition: an approach to drug development. Science, 267, 1782-1788 (1995)   DOI
32 Folkman, J., Anti-angiogenesis: new concepts for theraphy of solid tumors. Ann. Surg., 175, 409-416 (1972)   DOI   ScienceOn
33 Kuntz, I. D., Dock. 4.0 (University of California, San Francisco Web Site) (1998)
34 Olgen, S., Akaho, E., and Nebioglu, D., Evaluation of indole esters as inhibitors of $p60^{c-Src}$ receptor tyrosine kinase and investigation of the inhibition using receptor docking studies. J. Enzy. Inhib. Med. Chem. 18, 485-490 (2003)   DOI   ScienceOn
35 Widler, L., Green, J., Missbach, M., Susa, M., and Altmann, E., 7-Alkyl- and 7-cycloalkyl-5-aryl-pyrrolo[2, 3-d]pyrimidinespotent inhibitors of the tyrosine kinase c-Src. Bioorg. Med. Chem. Lett., 11, 849-852 (2001)   DOI   ScienceOn
36 Schulz-Gasch, T. and Stahl, M., Binding site characteristics in structure-based virtual screening: evaluation of current docking tools. J. Mol. Model., 9, 47-57 (2003)   DOI